Logo image of 1MEDP.MI

MEDPACE HOLDINGS INC (1MEDP.MI) Stock Fundamental Analysis

BIT:1MEDP - Euronext Milan - US58506Q1094 - Common Stock - Currency: EUR

387.7  +387.7 (+Infinity%)

Fundamental Rating

6

Overall 1MEDP gets a fundamental rating of 6 out of 10. We evaluated 1MEDP against 22 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making 1MEDP a very profitable company, without any liquidiy or solvency issues. 1MEDP is quite expensive at the moment. It does show a decent growth rate. These ratings would make 1MEDP suitable for quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

1MEDP had positive earnings in the past year.
In the past year 1MEDP had a positive cash flow from operations.
Each year in the past 5 years 1MEDP has been profitable.
In the past 5 years 1MEDP always reported a positive cash flow from operatings.
1MEDP.MI Yearly Net Income VS EBIT VS OCF VS FCF1MEDP.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

With an excellent Return On Assets value of 26.61%, 1MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
1MEDP has a better Return On Equity (242.70%) than 100.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 115.03%, 1MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for 1MEDP is significantly above the industry average of 12.40%.
The 3 year average ROIC (38.75%) for 1MEDP is below the current ROIC(115.03%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 26.61%
ROE 242.7%
ROIC 115.03%
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
1MEDP.MI Yearly ROA, ROE, ROIC1MEDP.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

1.3 Margins

With an excellent Profit Margin value of 18.74%, 1MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
1MEDP's Profit Margin has improved in the last couple of years.
1MEDP's Operating Margin of 21.40% is amongst the best of the industry. 1MEDP outperforms 95.45% of its industry peers.
1MEDP's Operating Margin has improved in the last couple of years.
The Gross Margin of 1MEDP (31.62%) is worse than 63.64% of its industry peers.
In the last couple of years the Gross Margin of 1MEDP has grown nicely.
Industry RankSector Rank
OM 21.4%
PM (TTM) 18.74%
GM 31.62%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
1MEDP.MI Yearly Profit, Operating, Gross Margins1MEDP.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1MEDP is creating value.
Compared to 1 year ago, 1MEDP has less shares outstanding
The number of shares outstanding for 1MEDP has been reduced compared to 5 years ago.
1MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
1MEDP.MI Yearly Shares Outstanding1MEDP.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
1MEDP.MI Yearly Total Debt VS Total Assets1MEDP.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

1MEDP has an Altman-Z score of 6.77. This indicates that 1MEDP is financially healthy and has little risk of bankruptcy at the moment.
1MEDP's Altman-Z score of 6.77 is amongst the best of the industry. 1MEDP outperforms 95.45% of its industry peers.
1MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.77
ROIC/WACC10.91
WACC10.54%
1MEDP.MI Yearly LT Debt VS Equity VS FCF1MEDP.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.3 Liquidity

1MEDP has a Current Ratio of 0.43. This is a bad value and indicates that 1MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
1MEDP's Current ratio of 0.43 is on the low side compared to the rest of the industry. 1MEDP is outperformed by 90.91% of its industry peers.
A Quick Ratio of 0.43 indicates that 1MEDP may have some problems paying its short term obligations.
1MEDP has a worse Quick ratio (0.43) than 90.91% of its industry peers.
The current and quick ratio evaluation for 1MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 0.43
Quick Ratio 0.43
1MEDP.MI Yearly Current Assets VS Current Liabilites1MEDP.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.53% over the past year.
Measured over the past years, 1MEDP shows a very strong growth in Earnings Per Share. The EPS has been growing by 33.22% on average per year.
1MEDP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.94%.
1MEDP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.62% yearly.
EPS 1Y (TTM)26.53%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%12.73%
Revenue 1Y (TTM)9.94%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%14.24%

3.2 Future

1MEDP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.31% yearly.
1MEDP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.53% yearly.
EPS Next Y2.91%
EPS Next 2Y3.1%
EPS Next 3Y5.56%
EPS Next 5Y8.31%
Revenue Next Year3.72%
Revenue Next 2Y3.54%
Revenue Next 3Y5.16%
Revenue Next 5Y6.53%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
1MEDP.MI Yearly Revenue VS Estimates1MEDP.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
1MEDP.MI Yearly EPS VS Estimates1MEDP.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5 10 15 20 25

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 33.25, which means the current valuation is very expensive for 1MEDP.
1MEDP's Price/Earnings ratio is in line with the industry average.
When comparing the Price/Earnings ratio of 1MEDP to the average of the S&P500 Index (27.61), we can say 1MEDP is valued slightly more expensively.
Based on the Price/Forward Earnings ratio of 33.30, the valuation of 1MEDP can be described as expensive.
Based on the Price/Forward Earnings ratio, 1MEDP is valued a bit more expensive than 77.27% of the companies in the same industry.
1MEDP is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 37.13, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 33.25
Fwd PE 33.3
1MEDP.MI Price Earnings VS Forward Price Earnings1MEDP.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

1MEDP's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. 1MEDP is more expensive than 63.64% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1MEDP indicates a somewhat cheap valuation: 1MEDP is cheaper than 68.18% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 22.16
EV/EBITDA 25.28
1MEDP.MI Per share data1MEDP.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1MEDP does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of 1MEDP may justify a higher PE ratio.
PEG (NY)11.44
PEG (5Y)1
EPS Next 2Y3.1%
EPS Next 3Y5.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 1MEDP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDPACE HOLDINGS INC

BIT:1MEDP (7/24/2025, 7:00:00 PM)

387.7

+387.7 (+Infinity%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)07-21 2025-07-21/amc
Earnings (Next)10-20 2025-10-20/amc
Inst Owners89.98%
Inst Owner ChangeN/A
Ins Owners0.54%
Ins Owner ChangeN/A
Market Cap11.14B
Analysts70
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.2%
Min EPS beat(2)2.57%
Max EPS beat(2)17.84%
EPS beat(4)4
Avg EPS beat(4)12.05%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.09%
EPS beat(12)11
Avg EPS beat(12)14.32%
EPS beat(16)15
Avg EPS beat(16)14.6%
Revenue beat(2)2
Avg Revenue beat(2)6.91%
Min Revenue beat(2)4.04%
Max Revenue beat(2)9.78%
Revenue beat(4)2
Avg Revenue beat(4)2.21%
Min Revenue beat(4)-3.35%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.5%
Revenue beat(12)7
Avg Revenue beat(12)1.63%
Revenue beat(16)8
Avg Revenue beat(16)1%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 33.25
Fwd PE 33.3
P/S 5.76
P/FCF 22.16
P/OCF 20.93
P/B 74.56
P/tB N/A
EV/EBITDA 25.28
EPS(TTM)11.66
EY3.01%
EPS(NY)11.64
Fwd EY3%
FCF(TTM)17.49
FCFY4.51%
OCF(TTM)18.53
OCFY4.78%
SpS67.33
BVpS5.2
TBVpS-15.81
PEG (NY)11.44
PEG (5Y)1
Profitability
Industry RankSector Rank
ROA 26.61%
ROE 242.7%
ROCE 135.95%
ROIC 115.03%
ROICexc 132.51%
ROICexgc N/A
OM 21.4%
PM (TTM) 18.74%
GM 31.62%
FCFM 25.98%
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.42
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 118.36%
Cap/Sales 1.54%
Interest Coverage 250
Cash Conversion 121.25%
Profit Quality 138.61%
Current Ratio 0.43
Quick Ratio 0.43
Altman-Z 6.77
F-Score8
WACC10.54%
ROIC/WACC10.91
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)26.53%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%12.73%
EPS Next Y2.91%
EPS Next 2Y3.1%
EPS Next 3Y5.56%
EPS Next 5Y8.31%
Revenue 1Y (TTM)9.94%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%14.24%
Revenue Next Year3.72%
Revenue Next 2Y3.54%
Revenue Next 3Y5.16%
Revenue Next 5Y6.53%
EBIT growth 1Y25.19%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year10.29%
EBIT Next 3Y8.11%
EBIT Next 5Y9.37%
FCF growth 1Y55.28%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y50.59%
OCF growth 3Y32.23%
OCF growth 5Y24.7%